miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $5.50 per share.

As quoted in the press release:

miRagen intends to use the net proceeds from this offering for working capital and general corporate purposes, which include the funding of clinical development of its product candidates, and general and administrative expenses.

Click here to read the full press release.